{"id":72139,"date":"2026-08-10T12:29:32","date_gmt":"2026-08-10T04:29:32","guid":{"rendered":"https:\/\/flcube.com\/?p=72139"},"modified":"2026-08-10T12:29:33","modified_gmt":"2026-08-10T04:29:33","slug":"hybio-files-first-tirzepatide-generic-anda-in-china-challenging-eli-lillys-glp-1-dominance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72139","title":{"rendered":"Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly&#8217;s GLP-1 Dominance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shenzhen Hybio Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/300199:SHE\">SHE:\u202f300199<\/a>) announced it has submitted a <strong>Class\u202f4 Chemical Abbreviated New Drug Application (ANDA)<\/strong> to China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> for its <strong>generic tirzepatide<\/strong>, targeting <strong>type\u202f2 diabetes<\/strong>, <strong>chronic weight management<\/strong>, and <strong>obstructive sleep apnea (OSA)<\/strong>. The filing positions Hybio as the <strong>first company globally<\/strong> to seek regulatory approval for a generic version of the blockbuster dual agonist originally developed by <strong>Eli Lilly &amp; Co.<\/strong><\/p>\n\n\n\n<h2 id=\"h-deal-snapshot\" class=\"wp-block-heading\">Deal Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE:\u202f300199)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Class\u202f4 Chemical ANDA (Abbreviated New Drug Application)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Generic tirzepatide<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Type\u202f2 diabetes; chronic weight management; OSA<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>08\u202fAug\u202f2026<\/td><\/tr><tr><td><strong>Originator<\/strong><\/td><td>Eli Lilly &amp; Co. (Mounjaro \/ Zepbound)<\/td><\/tr><tr><td><strong>Global Generic Status<\/strong><\/td><td>First generic filing worldwide (China + US)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Generic version of <strong>tirzepatide<\/strong><\/li>\n\n\n\n<li><strong>Class:<\/strong> <strong>Dual GLP\u20111R\/GIPR receptor agonist<\/strong><\/li>\n\n\n\n<li><strong>Original Developer:<\/strong> <strong>Eli Lilly &amp; Co.<\/strong>; marketed as <strong>Mounjaro<\/strong> (diabetes) and <strong>Zepbound<\/strong> (obesity)<\/li>\n\n\n\n<li><strong>Current Market Position:<\/strong> Holds a <strong>dominant position<\/strong> in the global obesity and diabetes drug markets; <strong>no generic versions<\/strong> are currently available anywhere in the world<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Simultaneously activates <strong>glucose\u2011dependent insulinotropic polypeptide (GIP)<\/strong> and <strong>glucagon\u2011like peptide\u20111 (GLP\u20111)<\/strong> receptors to enhance glycemic control, suppress appetite, and drive sustained weight loss<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-backdrop\" class=\"wp-block-heading\">Regulatory Backdrop<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Application Category<\/strong><\/td><td>Class\u202f4 Chemical ANDA<\/td><\/tr><tr><td><strong>Target Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Parallel Filing<\/strong><\/td><td>ANDA also submitted to <strong>US FDA<\/strong><\/td><\/tr><tr><td><strong>Indications Sought<\/strong><\/td><td>Type\u202f2 diabetes; chronic weight management; OSA<\/td><\/tr><tr><td><strong>Key Hurdle<\/strong><\/td><td>Patent\u2011clearance and bioequivalence validation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China GLP\u20111 Market:<\/strong> The domestic market for GLP\u20111\u2011based therapies is expanding rapidly as obesity and diabetes prevalence rises and reimbursement coverage broadens. A locally manufactured generic could significantly expand patient access.<\/li>\n\n\n\n<li><strong>First\u2011Mover Advantage:<\/strong> By filing in <strong>both China and the United States<\/strong>, Hybio is positioning itself as the global pioneer in the <strong>tirzepatide generic<\/strong> segment, potentially capturing meaningful market share before competitors enter the field.<\/li>\n\n\n\n<li><strong>Eli Lilly Dominance:<\/strong> Tirzepatide has become one of the best\u2011selling drugs globally, with analysts projecting annual sales exceeding <strong>$15\u202fbillion<\/strong>. A generic entry would pressure originator pricing and accelerate volume growth.<\/li>\n\n\n\n<li><strong>OSA Indication:<\/strong> The inclusion of <strong>obstructive sleep apnea<\/strong> as a target indication mirrors Eli Lilly\u2019s recent label\u2011expansion strategy and could open an additional, underserved commercial avenue for the generic.<\/li>\n\n\n\n<li><strong>Regulatory Timeline:<\/strong> Class\u202f4 ANDA reviews in China typically focus on bioequivalence and quality consistency; approval timelines will depend on NMPA prioritization, inspection scheduling, and clarity around the originator patent landscape.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the regulatory timeline, approval prospects, and commercial potential of Hybio\u2019s generic tirzepatide. Actual results may differ materially due to risks including patent litigation, bioequivalence study outcomes, NMPA review delays, competitive dynamics, and market acceptance. Investors should consult official filings for updated risk factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u7ff0\u5b87\u836f\u4e1a\uff1a\u5173\u4e8e\u66ff\u5c14\u6cca\u80bd\u6ce8\u5c04\u6db2\u9996\u4eff\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u7ff0\u5b87\u836f\u4e1a\uff1a\u5173\u4e8e\u66ff\u5c14\u6cca\u80bd\u6ce8\u5c04\u6db2\u9996\u4eff\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-79281611-18f4-42f2-bed5-db9b93b3d85c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u7ff0\u5b87\u836f\u4e1a\uff1a\u5173\u4e8e\u66ff\u5c14\u6cca\u80bd\u6ce8\u5c04\u6db2\u9996\u4eff\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\">\u7ff0\u5b87\u836f\u4e1a\uff1a\u5173\u4e8e\u66ff\u5c14\u6cca\u80bd\u6ce8\u5c04\u6db2\u9996\u4eff\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u7ff0\u5b87\u836f\u4e1a\uff1a\u5173\u4e8e\u66ff\u5c14\u6cca\u80bd\u6ce8\u5c04\u6db2\u9996\u4eff\u4e0a\u5e02\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-79281611-18f4-42f2-bed5-db9b93b3d85c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE:\u202f300199) announced it has submitted a Class\u202f4 Chemical Abbreviated New&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[42,287,38,4445,1106],"class_list":["post-72139","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-first-mover-generic","tag-hybio-pharmaceutical","tag-market-approval-filings","tag-metabolic-disease","tag-she-300199"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly&#039;s GLP-1 Dominance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE:\u202f300199) announced it has submitted a Class\u202f4 Chemical Abbreviated New Drug Application (ANDA) to China\u2019s National Medical Products Administration (NMPA) for its generic tirzepatide, targeting type\u202f2 diabetes, chronic weight management, and obstructive sleep apnea (OSA). The filing positions Hybio as the first company globally to seek regulatory approval for a generic version of the blockbuster dual agonist originally developed by Eli Lilly &amp; Co.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72139\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly&#039;s GLP-1 Dominance\" \/>\n<meta property=\"og:description\" content=\"Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE:\u202f300199) announced it has submitted a Class\u202f4 Chemical Abbreviated New Drug Application (ANDA) to China\u2019s National Medical Products Administration (NMPA) for its generic tirzepatide, targeting type\u202f2 diabetes, chronic weight management, and obstructive sleep apnea (OSA). The filing positions Hybio as the first company globally to seek regulatory approval for a generic version of the blockbuster dual agonist originally developed by Eli Lilly &amp; Co.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72139\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T04:29:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T04:29:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72139#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72139\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly&#8217;s GLP-1 Dominance\",\"datePublished\":\"2026-08-10T04:29:32+00:00\",\"dateModified\":\"2026-08-10T04:29:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72139\"},\"wordCount\":475,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"First-mover generic\",\"Hybio Pharmaceutical\",\"Market approval filings\",\"Metabolic disease\",\"SHE: 300199\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72139#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72139\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72139\",\"name\":\"Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly's GLP-1 Dominance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-10T04:29:32+00:00\",\"dateModified\":\"2026-08-10T04:29:33+00:00\",\"description\":\"Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE:\u202f300199) announced it has submitted a Class\u202f4 Chemical Abbreviated New Drug Application (ANDA) to China\u2019s National Medical Products Administration (NMPA) for its generic tirzepatide, targeting type\u202f2 diabetes, chronic weight management, and obstructive sleep apnea (OSA). The filing positions Hybio as the first company globally to seek regulatory approval for a generic version of the blockbuster dual agonist originally developed by Eli Lilly & Co.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72139#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72139\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72139#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly&#8217;s GLP-1 Dominance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly's GLP-1 Dominance - Insight, China&#039;s Pharmaceutical Industry","description":"Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE:\u202f300199) announced it has submitted a Class\u202f4 Chemical Abbreviated New Drug Application (ANDA) to China\u2019s National Medical Products Administration (NMPA) for its generic tirzepatide, targeting type\u202f2 diabetes, chronic weight management, and obstructive sleep apnea (OSA). The filing positions Hybio as the first company globally to seek regulatory approval for a generic version of the blockbuster dual agonist originally developed by Eli Lilly & Co.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72139","og_locale":"en_US","og_type":"article","og_title":"Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly's GLP-1 Dominance","og_description":"Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE:\u202f300199) announced it has submitted a Class\u202f4 Chemical Abbreviated New Drug Application (ANDA) to China\u2019s National Medical Products Administration (NMPA) for its generic tirzepatide, targeting type\u202f2 diabetes, chronic weight management, and obstructive sleep apnea (OSA). The filing positions Hybio as the first company globally to seek regulatory approval for a generic version of the blockbuster dual agonist originally developed by Eli Lilly & Co.","og_url":"https:\/\/flcube.com\/?p=72139","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-10T04:29:32+00:00","article_modified_time":"2026-08-10T04:29:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72139#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72139"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly&#8217;s GLP-1 Dominance","datePublished":"2026-08-10T04:29:32+00:00","dateModified":"2026-08-10T04:29:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72139"},"wordCount":475,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["First-mover generic","Hybio Pharmaceutical","Market approval filings","Metabolic disease","SHE: 300199"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72139#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72139","url":"https:\/\/flcube.com\/?p=72139","name":"Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly's GLP-1 Dominance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-10T04:29:32+00:00","dateModified":"2026-08-10T04:29:33+00:00","description":"Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE:\u202f300199) announced it has submitted a Class\u202f4 Chemical Abbreviated New Drug Application (ANDA) to China\u2019s National Medical Products Administration (NMPA) for its generic tirzepatide, targeting type\u202f2 diabetes, chronic weight management, and obstructive sleep apnea (OSA). The filing positions Hybio as the first company globally to seek regulatory approval for a generic version of the blockbuster dual agonist originally developed by Eli Lilly & Co.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72139#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72139"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72139#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly&#8217;s GLP-1 Dominance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72139"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72139\/revisions"}],"predecessor-version":[{"id":72141,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72139\/revisions\/72141"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}